Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BO-112 plus pembrolizumab in anti-PD-1-refractory unresectable melanoma
2020-003921-51Phase 2Completed
- Sponsor
- Highlight Therapeutics
- Start
- Nov 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Oncolytic Viruses → Oncolytic Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nanoplexed poly I:C and pembrolizumab in melanoma, sponsored by Highlight Therapeutics. Primary endpoint: Objective response rate. Started Nov 2020; status: completed.
02
Drugs
nanoplexed poly I:Cpembrolizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2020-003921-51.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003921-51.